Introduction: The regulatory framework of Australia (TGA) covers laws, guidelines, and processes that ensure the safety, quality and efficacy of therapeutic goods. For B. Pharm students, understanding TGA roles, the Australian Register of Therapeutic Goods (ARTG), AUST R vs AUST L listings, Good Manufacturing Practice (GMP), clinical trial schemes, post‑marketing surveillance, advertising rules, scheduling (Poisons Standard) and access pathways (SAS, Authorised Prescriber, provisional approval) is essential. This knowledge supports safe product development, registration, pharmacovigilance and compliance with Australian requirements. The following 30 MCQs with answers will deepen your practical grasp of TGA systems and prepare you for exams and professional practice. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What is the primary role of the Therapeutic Goods Administration (TGA) in Australia?
- To manufacture medicines for public hospitals
- To regulate the quality, safety and efficacy of therapeutic goods
- To set prices for prescription medicines
- To provide clinical care to patients
Correct Answer: To regulate the quality, safety and efficacy of therapeutic goods
Q2. Which register lists medicines that are approved for supply in Australia?
- Australian Drug Directory (ADD)
- Australian Register of Therapeutic Goods (ARTG)
- National Pharmaceutical Index (NPI)
- Medicines Approval List (MAL)
Correct Answer: Australian Register of Therapeutic Goods (ARTG)
Q3. What is the key difference between AUST R and AUST L medicines?
- AUST R are registered (evaluated for safety and efficacy); AUST L are listed (lower-risk, assessed for safety only)
- AUST R are for veterinary use; AUST L are for human use
- AUST R are over-the-counter; AUST L are prescription-only
- AUST R are imported; AUST L are locally manufactured
Correct Answer: AUST R are registered (evaluated for safety and efficacy); AUST L are listed (lower-risk, assessed for safety only)
Q4. Which document determines the scheduling of medicines (e.g., S2, S4) in Australia?
- Australian Clinical Trials Manual
- Poisons Standard (SUSMP)
- Therapeutic Goods Act Schedule
- National Drug Compendium
Correct Answer: Poisons Standard (SUSMP)
Q5. Who is usually responsible for submitting an application to include a medicine on the ARTG?
- The prescribing physician
- The product sponsor (Australian sponsor)
- The patient advocacy group
- The hospital pharmacy
Correct Answer: The product sponsor (Australian sponsor)
Q6. Which pathway allows early access to promising medicines in Australia before full registration?
- Special Access Scheme (SAS)
- Provisional Approval pathway
- Over-the-counter switch
- Automatic registration
Correct Answer: Provisional Approval pathway
Q7. The Special Access Scheme (SAS) is mainly used to:
- Provide discounted drugs to pharmacies
- Allow access to unregistered therapeutic goods for individual patients
- Authorize advertising of new medicines
- Register generic medicines automatically
Correct Answer: Allow access to unregistered therapeutic goods for individual patients
Q8. Which of the following is a requirement for sponsors regarding manufacturing standards?
- Maintain Good Manufacturing Practice (GMP) certification
- Manufacture only in hospitals
- Use only locally sourced raw materials
- Avoid any quality audits
Correct Answer: Maintain Good Manufacturing Practice (GMP) certification
Q9. What is the purpose of a Risk Management Plan (RMP) or Pharmacovigilance Plan submitted to the TGA?
- To outline marketing strategies for a product
- To describe measures to monitor and minimize safety risks
- To list all manufacturing sites worldwide
- To set the retail price of a medicine
Correct Answer: To describe measures to monitor and minimize safety risks
Q10. Which scheme requires ethics committee approval and notification to state regulators before clinical trial commencement?
- Clinical Trial Notification (CTN) scheme
- Over-the-counter supply scheme
- Authorised Prescriber scheme
- Provisional Listing scheme
Correct Answer: Clinical Trial Notification (CTN) scheme
Q11. Advertising of prescription medicines to the general public in Australia is:
- Allowed without restriction
- Strictly prohibited
- Allowed only for AUST L medicines
- Managed by local pharmacies
Correct Answer: Strictly prohibited
Q12. Which Australian regulatory pathway is commonly used for low-risk complementary medicines?
- AUST R registration
- AUST L listing
- Special Access Scheme (SAS)
- Provisional Approval
Correct Answer: AUST L listing
Q13. What must a sponsor do when a serious adverse event associated with their registered medicine is identified?
- Ignore it unless media reports it
- Report it to the TGA and take appropriate safety actions
- Only record it in the company file
- Withdraw the product immediately without notification
Correct Answer: Report it to the TGA and take appropriate safety actions
Q14. Medical devices in Australia are regulated by the TGA and are required to be:
- Listed or included on the ARTG depending on device class
- Automatically available without any regulatory control
- Sold only through hospitals
- Excluded from conformity assessment
Correct Answer: Listed or included on the ARTG depending on device class
Q15. Which of the following describes the role of an Australian sponsor?
- Manufacture all products in Australia
- Act as the local responsible entity for regulatory submissions and post-market obligations
- Provide clinical care to trial participants
- Set international prices for medicines
Correct Answer: Act as the local responsible entity for regulatory submissions and post-market obligations
Q16. What is the TGA’s approach to international GMP inspections and recognition?
- It does not consider overseas evidence
- It uses international inspections and mutual recognition to assess GMP compliance
- It requires all manufacturers to be located in Australia
- It relies solely on sponsor statements
Correct Answer: It uses international inspections and mutual recognition to assess GMP compliance
Q17. Which document must accompany a registered prescription medicine to inform patients?
- Consumer Medicine Information (CMI)
- Marketing Brochure
- Price List
- Manufacturing SOP
Correct Answer: Consumer Medicine Information (CMI)
Q18. The Authorised Prescriber scheme allows which of the following?
- Prescribing unapproved therapeutic goods to listed patients under approval
- Automatic public subsidy for new drugs
- Unrestricted advertising of all medicines
- Over-the-counter sale of prescription drugs
Correct Answer: Prescribing unapproved therapeutic goods to listed patients under approval
Q19. What type of evidence does the TGA usually require for full registration of a new medicine?
- Robust clinical data demonstrating safety and efficacy
- Only anecdotal case reports
- Marketing plans and sales forecasts
- Evidence of use in other markets only
Correct Answer: Robust clinical data demonstrating safety and efficacy
Q20. Which pathway is most appropriate for a clinician seeking immediate access for a single critically ill patient to an unapproved medicine?
- Product listing on ARTG
- Special Access Scheme (SAS), Category A or B
- Provisional Approval pathway
- Over-the-counter switch
Correct Answer: Special Access Scheme (SAS), Category A or B
Q21. What is an example of a post-marketing regulatory action the TGA may take?
- Issuing a recall for a defective batch
- Approving a product without review
- Mandating free samples to consumers
- Removing all quality requirements
Correct Answer: Issuing a recall for a defective batch
Q22. Which committee provides expert advice on medicine scheduling to the Australian government?
- Advisory Committee on Medicines Scheduling (ACMS)
- National Price Committee
- Pharmacy Accreditation Board
- Clinical Trials Board
Correct Answer: Advisory Committee on Medicines Scheduling (ACMS)
Q23. Electronic Common Technical Document (eCTD) is used for:
- Submitting regulatory dossiers for prescription medicine approvals
- Label printing only
- Compounding sterile preparations
- Hospital inventory management
Correct Answer: Submitting regulatory dossiers for prescription medicine approvals
Q24. Which of the following is true about advertising complementary medicines in Australia?
- Advertising must comply with TGA and Australian Consumer Law and be truthful and not misleading
- They can claim to cure serious diseases without evidence
- There are no rules for advertising listed medicines
- Advertising is banned for all complementary medicines
Correct Answer: Advertising must comply with TGA and Australian Consumer Law and be truthful and not misleading
Q25. When importing therapeutic goods into Australia for commercial supply, the importer must ensure:
- The goods are included or listed on the ARTG or otherwise authorized
- No documentation is required
- Products are always treated as free samples
- Customs handles all regulatory compliance
Correct Answer: The goods are included or listed on the ARTG or otherwise authorized
Q26. What does GMP stand for and why is it important?
- Good Marketing Practices; to promote sales
- Great Manufacturing Process; to reduce costs
- Good Manufacturing Practice; to ensure consistent product quality and safety
- General Medical Procedures; for clinical practice
Correct Answer: Good Manufacturing Practice; to ensure consistent product quality and safety
Q27. Which of these is a potential outcome if a sponsor breaches TGA regulatory requirements?
- Regulatory action including fines, product recall or suspension
- Automatic award of marketing exclusivity
- Immediate patent extension
- Guaranteed approval of another product
Correct Answer: Regulatory action including fines, product recall or suspension
Q28. For a listed (AUST L) medicine, which statement about ingredients and claims is correct?
- Claims must be limited to low-risk indications and supported by evidence
- Claims can include life-saving disease cures without evidence
- There are no restrictions on ingredients
- Listed medicines must include full clinical trial reports
Correct Answer: Claims must be limited to low-risk indications and supported by evidence
Q29. What is the main purpose of the ARTG entry for a therapeutic good?
- To authorize lawful supply of the product in Australia
- To record the retail price
- To provide marketing materials for pharmacies
- To exempt the product from quality checks
Correct Answer: To authorize lawful supply of the product in Australia
Q30. Which mechanism allows the TGA to require removal or correction of misleading promotional material?
- Regulatory enforcement and compliance actions under the Therapeutic Goods legislation
- Issuing a medical licence to the advertiser
- Automatically listing the product on the ARTG
- Providing free advertising space to competitors
Correct Answer: Regulatory enforcement and compliance actions under the Therapeutic Goods legislation
